School of Pharmaceutical Science, Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, China; School of Basic Medical Science, Kunming Medical University, Kunming 650500, China.
Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College, Kunming 650118, China.
Infect Genet Evol. 2018 Oct;64:241-248. doi: 10.1016/j.meegid.2018.07.002. Epub 2018 Jul 2.
Human papillomavirus type 16 (HPV16) is considered to be the primary pathogen related to cervical cancer. The HPV16 E2 protein plays an important role in tumourigenicity of cervical carcinoma. In the current study, we enrolled 121 HPV16-positive cervical cancer patients in the case group and 130 HPV16-positive asymptomatic individuals in the control group, and we investigated the association between HPV16 E2 gene variations and cervical cancer. The HPV16 E2 DNA was amplified and sequenced. We identified two HPV variants (EUR and As) in the control group; the As variant was predominant (68.5%), followed by the EUR variant (31.5%). In the case group, three HPV variants (EUR, As and AA) were observed; the As variant was predominant (72.7%), followed by the EUR variant (22.3%) and the AA variant (5.0%). Our results showed a significant difference in the distribution of the HPV16 variants between the case and control groups (P < 0.05). Moreover, in the HPV16 E2 gene variation analysis, the distribution of sixteen variations was significantly different between the case and control groups (P < 0.05), and all of these variations were present in the AA variant. In the subgroup analysis, the frequency of the T3575G (S274A) variation in the EUR variant was significantly different between the case and control groups (P = 0.029); however, there was no significant difference in the frequency of the variations in the As variant between the case and control groups. Our findings in the current study could provide a better understanding of the relationship between HPV16 variants, E2 gene variations and cervical cancer.
人乳头瘤病毒 16 型(HPV16)被认为是与宫颈癌相关的主要病原体。HPV16 E2 蛋白在宫颈癌的致瘤性中发挥重要作用。在本研究中,我们纳入了 121 例 HPV16 阳性宫颈癌患者作为病例组和 130 例 HPV16 阳性无症状个体作为对照组,研究 HPV16 E2 基因变异与宫颈癌的关系。扩增并测序 HPV16 E2 DNA。我们在对照组中发现了两种 HPV 变体(EUR 和 As);As 变体占优势(68.5%),其次是 EUR 变体(31.5%)。在病例组中,观察到三种 HPV 变体(EUR、As 和 AA);As 变体占优势(72.7%),其次是 EUR 变体(22.3%)和 AA 变体(5.0%)。我们的结果显示 HPV16 变体在病例组和对照组中的分布存在显著差异(P<0.05)。此外,在 HPV16 E2 基因变异分析中,病例组和对照组之间十六种变异的分布存在显著差异(P<0.05),所有这些变异均存在于 AA 变体中。在亚组分析中,EUR 变体中 T3575G(S274A)变异的频率在病例组和对照组之间存在显著差异(P=0.029);然而,As 变体中变异的频率在病例组和对照组之间没有差异。本研究的发现可以更好地理解 HPV16 变体、E2 基因变异与宫颈癌之间的关系。